What development stage is Saltikva at?

A pivotal Phase 3 in stage IV metastatic pancreatic cancer is planned following an FDA Type C meeting; it is not yet active or recruiting. Saltikva, the lead product candidate of Salspera, Inc., is investigational and not approved by the FDA, and the company has no products approved for sale. Saltikva has been studied in a Phase 1 trial sponsored by the University of Minnesota (NCT01099631 ↗) and in an open-label, non-randomized Phase 2 trial in metastatic pancreatic cancer (NCT04589234 ↗). ClinicalTrials.gov lists the Phase 2 as active, not recruiting.